Turkiye Klinikleri Journal of Medical Sciences

.: REVIEW
Üçlü Negatif Meme Kanserinde Nanomalzeme Temelli Tedavi Stratejileri: Geleneksel Derleme
Nanomaterial Based Treatment Strategies in Triple Negative Breast Cancer: Traditional Review
İsmail Mert ALKAÇa, Burçak VURALb
aEge Üniversitesi Sağlık Bilimleri Enstitüsü, Tıbbi Biyoloji ABD, İzmir, TÜRKİYE
bİstanbul Üniversitesi Aziz Sancar Deneysel Tıp Araştırma Enstitüsü, Genetik ABD, İstanbul, TÜRKİYE
Turkiye Klinikleri J Med Sci. 2021;41(4):491-500
doi: 10.5336/medsci.2021-84439
Article Language: TR
Full Text
ÖZET
 Malzeme bilimi ve nanoteknolojideki gelişmeler, nanomalzeme temelli ilaçları kanser tedavisi için potansiyel bir araç olarak ortaya çı- karmıştır. Böylece antikanser ilaçlarının nanomalzemeden yapılmış bir paketleme sistemine yüklenerek kanserli hücreye hedeflenmesi, antikanser ilaçların toksisitesini azaltmak, etkinliğini ve dolaşım sürecini artırmak ve hatta hücre yüzey belirtecine özgü antijenler aracılığı ile ilacı, kanser hücrelerine özgü hale getirilmesi mümkün olmuştur. Üçlü negatif meme kanseri, östrojen ve progesteron hormon reseptörlerinin olmayışı ve İnsan epidermal büyüme faktör reseptörü-2 (HER2)'nin ifade edilmemesiyle karakterize olan, tüm meme kanseri vakalarının %15-20'sini oluşturan oldukça invaziv ve metastatik özelliklere sahip kötü prognoz ile seyreden kötü huylu tümörlerden biridir. Üçlü negatif meme kan seri olan hastalar, hücre yüzeyi reseptörlerini hedef alan hormonal veya trastuzumab bazlı tedavilerden fayda görmez. Hâlâ birçok kemotera pötik ilaç, etkili dozlarda tümör bölgesine ulaşamamaktadır ve genel likle yüksek sistemik toksisite ve zayıf farmakokinetik özellik göstermektedir. Bu nedenle üçlü negatif meme kanseri tedavisindeki klinik zorlukların üstesinden gelmek için potansiyel terapötik seçenek- ler olarak geniş bir yelpazede nanoteknoloji tabanlı platformlar araştı- rılmaktadır. Terapötik ajanların, meme kanseri tümörlerine verilme etkinliğini artırmak için tümör hücrelerini, tümör vaskülarizasyonunu ve tümör mikro ortamını hedeflemek için çeşitli nanopartikül ilaç taşı- yıcıları geliştirilmiştir. Bu derlemede, üçlü negatif meme kanserinin na- nomateryaller aracılığı ile tedavi stratejilerini ayrıntılı bir şekilde tartışıyoruz ve bu konuda bir bakış açısı sunmayı hedefliyoruz.

Anahtar Kelimeler: Üçlü negatif meme kanseri; nanomalzeme; antikanser ilaç; ilaç taşıma sistemleri
ABSTRACT
 Advances in materials science and nanotechnology have revealed nanomaterial-based drugs as a potential tool for cancer treat- ment. Thus, it has been possible to target anticancer drugs to cancer cells by loading them into a packaging system made of nanomaterials, to reduce the toxicity of anticancer drugs, to increase their efficiency and circulation process, and even to make the drug specific to cancer cells by means of cell surface marker-specific antigens. Triple negative breast cancer, is one of the malignant tumors characterized by the absence of estrogen and progesterone hormone receptors and under-expression of Human epidermal growth factor receptor-2 (HER2), is highly invasive, accounting for 15-20% of all breast cancer cases, and has a poor prognosis with metastatic features. Patients with triple negative breast cancer do not benefit from hormonal or trastuzumab-based treatments that target cell surface receptors. Still, many chemotherapeutic drugs do not reach the tumor site in effective doses and generally show high systemic toxicity and poor pharmacokinetics. Therefore, a wide range of nanotechnology-based platforms are being explored as potential therapeutic options to overcome the clinical challenges of triple negative breast cancer ther apy. To increase the efficacy of delivering therapeutic agents to breast cancer tumors, various nanoparticle drug carriers have been developed to target tumor cells, tumor vascularisation and tumor microenviron ment. In this review, we discuss the treatment strategies of triple nega tive breast cancer through nanomaterials in detail and we aim to present a perspective on this issue.

Keywords: Triple negative breast cancer; nanomaterial; anticancer drug; drug delivery systems
REFERENCES:
  1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi-eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53. [Crossref]  [PubMed] 
  2. Goldman E, Zinger A, da Silva D, Yaari Z, Kajal A, Vardi-Oknin D, et al. Nanoparticles target early-stage breast cancer metastasis in vivo. Nanotechnology. 2017;28(43):43LT01. [Crossref]  [PubMed] 
  3. Xie Z, Zeng X. DNA/RNA-based formulations for treatment of breast cancer. Expert Opin Drug Deliv. 2017;14(12):1379-93. [Crossref]  [PubMed] 
  4. Rocha M, Chaves N, Báo S. Nanobiotechnology for breast cancer treatment. In: Van Pham P, ed. Breast Cancer: From Biology to Medicine. 1st ed. Croatia: IntechOpen; 2017. p.411-32. [Crossref] 
  5. Feng B, Niu Z, Hou B, Zhou L, Li Y, Yu H. Enhancing triple negative breast cancer ımmunotherapy by ICG-templated self-assembly of paclitaxel nanoparticles. Adv Funct Mater. 2020;30(6):1906605. [Crossref] 
  6. Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12(2):106-16. [PubMed]  [PMC] 
  7. Jain V, Kumar H, Anod HV, Chand P, Gupta NV, Dey S, et al. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. J Control Release. 2020;326:628-47. [Crossref]  [PubMed] 
  8. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. [Crossref]  [PubMed] 
  9. Khanna V, Kalscheuer S, Kirtane A, Zhang W, Panyam J. Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer. Future Drug Discov. 2019;1(1):FDD8. [Crossref]  [PubMed]  [PMC] 
  10. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Türkiye Kanser İstatistikleri, 2016. Ankara: 2019. Erişim linki: [Link] 
  11. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366(2):109-19. [Crossref]  [PubMed]  [PMC] 
  12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717. [Crossref]  [PubMed] 
  13. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-81. [Crossref]  [PubMed] 
  14. Miller-Kleinhenz JM, Bozeman EN, Yang L. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(6):797-816. [Crossref]  [PubMed]  [PMC] 
  15. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010;16(1):53-61. [Crossref]  [PubMed]  [PMC] 
  16. Lu RM, Chen MS, Chang DK, Chiu CY, Lin WC, Yan SL, et al. Targeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imaging. PLoS One. 2013;8(6):e66128. [Crossref]  [PubMed]  [PMC] 
  17. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004; 4(10):806-13. [Crossref]  [PubMed] 
  18. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99(19): 1441-54. [Crossref]  [PubMed] 
  19. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138-57. [Crossref]  [PubMed] 
  20. Hida K, Maishi N, Sakurai Y, Hida Y, Harashima H. Heterogeneity of tumor endothelial cells and drug delivery. Adv Drug Deliv Rev. 2016;99(Pt B):140-7. [Crossref]  [PubMed] 
  21. Sajja HK, East MP, Mao H, Wang YA, Nie S, Yang L. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol. 2009;6(1):43-51. [Crossref]  [PubMed]  [PMC] 
  22. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009;9(5):1909-15. [Crossref]  [PubMed] 
  23. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1-16. [Crossref]  [PubMed] 
  24. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol. 2003;21(10):1184-91. [Crossref]  [PubMed] 
  25. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-71. [Crossref]  [PubMed] 
  26. Forssen EA, Ross ME. Daunoxome® treatment of solid tumors: Preclinical and clinical investigations. J Liposome Res. 1994;4(1): 481-512. [Crossref] 
  27. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48. [Crossref]  [PubMed] 
  28. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-60. [Crossref]  [PubMed] 
  29. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-98. [Crossref]  [PubMed] 
  30. Miller-Kleinhenz JM, Bozeman EN, Yang L. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(6):797-816. [Crossref]  [PubMed]  [PMC] 
  31. Litzinger DC, Buiting AM, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta. 1994; 1190(1):99-107. [Crossref]  [PubMed] 
  32. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther. 2001;298(2):607-12. [PubMed] 
  33. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991;1068(2): 133-41. [Crossref]  [PubMed] 
  34. Liu J, Dong J, Zhang T, Peng Q. Graphene-based nanomaterials and their potentials in advanced drug delivery and cancer therapy. J Control Release. 2018;286:64-73. [Crossref]  [PubMed] 
  35. Yao J, Sun Y, Yang M, Duan Y. Chemistry, physics and biology of graphene-based nanomaterials: new horizons for sensing, imaging and medicine. J Mater Chem. 2012;22;14313-29. [Crossref] 
  36. Zhu Y, Murali S, Cai W, Li X, Suk JW, Potts JR, et al. Graphene and graphene oxide: synthesis, properties, and applications. Adv Mater. 2010;22(35):3906-24. Erratum in: Adv Mater. 2010;22(46):5226. [Crossref]  [PubMed] 
  37. Wei Y, Zhou F, Zhang D, Chen Q, Xing D. A graphene oxide based smart drug delivery system for tumor mitochondria-targeting photodynamic therapy. Nanoscale. 2016;8(6): 3530-8. [Crossref]  [PubMed] 
  38. Wu J, Chen A, Qin M, Huang R, Zhang G, Xue B, et al. Hierarchical construction of a mechanically stable peptide-graphene oxide hybrid hydrogel for drug delivery and pulsatile triggered release in vivo. Nanoscale. 2015; 7(5):1655-60. [Crossref]  [PubMed] 
  39. Kiew SF, Ho YT, Kiew LV, Kah JCY, Lee HB, Imae T, et al. Preparation and characterization of an amylase-triggered dextrin-linked graphene oxide anticancer drug nanocarrier and its vascular permeability. Int J Pharm. 2017;534(1-2):297-307. [Crossref]  [PubMed] 
  40. Siriviriyanun A, Tsai YJ, Voon SH, Kiew SF, Imae T, Kiew LV, et al. Cyclodextrin- and dendrimer-conjugated graphene oxide as a nanocarrier for the delivery of selected chemotherapeutic and photosensitizing agents. Mater Sci Eng C Mater Biol Appl. 2018;89:307-15. [Crossref]  [PubMed] 
  41. Das M, Mohanty C, Sahoo SK. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv. 2009;6(3):285-304. [Crossref]  [PubMed] 
  42. Ying X, Wen H, Lu WL, Du J, Guo J, Tian W, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010; 141(2):183-92. [Crossref]  [PubMed] 
  43. Kulhari H, Pooja D, Shrivastava S, V G M N, Sistla R. Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel. Colloids Surf B Biointerfaces. 2014;117:166-73. [Crossref]  [PubMed] 
  44. Schultz JF, Bell JD, Goldstein RM, Kuhn JA, McCarty TM. Hepatic tumor imaging using iron oxide MRI: comparison with computed tomography, clinical impact, and cost analysis. Ann Surg Oncol. 1999;6(7):691-8. [Crossref]  [PubMed] 
  45. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348(25):2491-9. Erratum in: N Engl J Med. 2003;349(10):1010. [Crossref]  [PubMed] 
  46. Qiao W, Wang B, Wang Y, Yang L, Zhang Y, Shao P. Cancer therapy based on nanomaterials and nanocarrier systems. Journal of Nanomaterials. 2010:1-9. [Crossref] 
  47. Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006;12(5):1606-14. [Crossref]  [PubMed] 
  48. Lee SM, Ahn RW, Chen F, Fought AJ, O'Halloran TV, Cryns VL, et al. Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano. 2010;4(9):4971-8. [Crossref]  [PubMed]  [PMC] 
  49. Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 2014;35(14):4333-44. [Crossref]  [PubMed] 
  50. Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release. 2013;171(3):280-7. [Crossref]  [PubMed] 
  51. Zhou W, Zhou Y, Wu J, Liu Z, Zhao H, Liu J, et al. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells. J Drug Target. 2014; 22(1):57-66. [Crossref]  [PubMed] 
  52. Zhang C, Zhang X, Zhao W, Zeng C, Li W, Li B, et al. Chemotherapy drugs derived nano particles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. Nano Res. 2019;12(4): 855-61. [Crossref]  [PubMed]  [PMC] 
  53. Soma CE, Dubernet C, Bentolila D, Benita S, Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials. 2000;21(1):1-7. [Crossref]  [PubMed] 
  54. Jain RK, Stylianopoulos T. Delivering nano medicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653-64. [Crossref]  [PubMed]  [PMC] 
  55. Sykes EA, Chen J, Zheng G, Chan WC. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano. 2014;8(6):5696-706. [Crossref]  [PubMed] 
  56. Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res. 2011;44(10):1123-34. [Crossref]  [PubMed] 
  57. Liang C, Yang Y, Ling Y, Huang Y, Li T, Li X. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. Bioorg Med Chem. 2011;19(13):4057-66. [Crossref]  [PubMed] 
  58. Sutradhar KB, Amin L. Nanotechnology in cancer drug delivery and selective targeting. ISRN Nanotechnol. 2014:1-12. [Crossref] 
  59. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res. 2003;20(9):1337-50. [Crossref]  [PubMed] 
  60. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41:189-207. [Crossref]  [PubMed] 
  61. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-84. [Crossref]  [PubMed] 
  62. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62(3):284-304. [Crossref]  [PubMed]  [PMC] 
  63. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161(2):175-87. [Crossref]  [PubMed] 
  64. Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J, Prina-Mello A. Nano medicine applied to translational oncology: A future perspective on cancer treatment. Nano medicine. 2016;12(1):81-103. [Crossref]  [PubMed] 
  65. Wang Y, Santos A, Evdokiou A, Losic D. An overview of nanotoxicity and nanomedicine research: principles, progress and implications for cancer therapy. J Mater Chem B. 2015; 3(36):7153-72. [Crossref]  [PubMed] 
  66. Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg. 2019;6(1):23. [Crossref]  [PubMed]  [PMC] 
  67. Inoue K, Takano H. Aggravating impact of nanoparticles on immune-mediated pulmonary inflammation. ScientificWorldJournal. 2011;11:382-90. [Crossref]  [PubMed]  [PMC] 
  68. Garnett MC, Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. Occup Med (Lond). 2006;56(5):307-11. [Crossref]  [PubMed] 
  69. Baati T, Njim L, Neffati F, Kerkeni A, Bouttemi M, Gref R, et al. In depth analysis of the in vivo toxicity of nanoparticles of porous iron(iii) metal-organic frameworks. Chem Sci. 2013;4(4):1597-607. [Crossref] 
  70. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A. 2006;103(13):4930-4. [Crossref]  [PubMed] 
  71. Suh WH, Suslick KS, Stucky GD, Suh YH. Nanotechnology, nanotoxicology, and neuroscience. Prog Neurobiol. 2009;87(3):133-70. [Crossref]  [PubMed]  [PMC] 
  72. Elena V, Gazouli M, Ploussi A, Platoni K, Efstathopoulos EP. Nanoparticles: nanotoxicity aspects. J Phys: Conf Ser. 2017;931(1):1-6. [Crossref] 
  73. Walters C, Pool E, Somerset V. Nanotoxico-logy: a review. In: Soloneski S, Larramendy ML, et al. Toxicology: New Aspects to This Scientific Conundrum. 1st ed. Croatia: IntechOpen; 2016. p.45-64.
  74. Chitgupi U, Qin Y, Lovell JF. Targeted nanomaterials for phototherapy. Nanotheranostics. 2017;1(1):38-58. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com